Growth Metrics

Adma Biologics (ADMA) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $137.7 million.

  • Adma Biologics' Receivables - Net rose 17457.72% to $137.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.7 million, marking a year-over-year increase of 17457.72%. This contributed to the annual value of $50.0 million for FY2024, which is 8233.84% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Receivables - Net is $137.7 million, which was up 17457.72% from $109.7 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Receivables - Net registered a high of $137.7 million during Q3 2025, and its lowest value of $15.4 million during Q1 2021.
  • For the 5-year period, Adma Biologics' Receivables - Net averaged around $43.0 million, with its median value being $28.6 million (2021).
  • As far as peak fluctuations go, Adma Biologics' Receivables - Net tumbled by 4574.28% in 2022, and later soared by 26438.08% in 2025.
  • Adma Biologics' Receivables - Net (Quarter) stood at $28.6 million in 2021, then crashed by 45.74% to $15.5 million in 2022, then soared by 76.85% to $27.4 million in 2023, then surged by 82.34% to $50.0 million in 2024, then skyrocketed by 175.35% to $137.7 million in 2025.
  • Its last three reported values are $137.7 million in Q3 2025, $109.7 million for Q2 2025, and $99.4 million during Q1 2025.